Angiosarcoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The linings of blood and lymph vessels can become affected by the uncommon cancer known as angiosarcoma. This cancer can develop anywhere in the body, but the skin, breast, liver, and spleen are the most typical sites of involvement. For 1-2% of all soft tissue sarcomas in humans, angiosarcoma is a highly malignant ependymoma. Less than 0.01% of head and neck malignancies, including angiosarcoma, occur in the head and neck. Angiosarcomas account for about 2% of soft tissue tumors overall and 54% of cutaneous soft tissue tumors. With a high rate of nearby and distant recurrence, angiosarcoma is a highly malignant ependymoma. Histological examination is the only reliable technique for making a precise diagnosis of angiosarcoma due to its diverse pathological makeup.

Description

A rare form of cancer called angiosarcoma appears in the linings of blood and lymph vessels. Although it can develop anywhere in the body, this cancer typically affects the skin, breast, liver, and spleen. 1-2 % of all soft tissue sarcomas in humans are angiosarcomas, a particularly dangerous ependymoma. A history of radiation exposure, certain familial syndromes, environmental carcinogens, and chronic lymphedema are some of the specific risk factors for angiosarcoma, though the exact cause is unknown. Although diagnostic tools like ultrasound, computed tomography, and magnetic resonance imaging are available, pathological and immunohistochemical confirmation are still necessary for a firm diagnosis. The majority of angiosarcoma cases are cutaneous or cutaneous angiosarcomas, which are typically found on the scalp and face. Subcutaneous hemangiosarcomas are angiosarcomas that form beneath the skin's surface. Angiosarcomas occur in deep tissue in about 25% of cases, and breast tissue in about 8% of cases. Lymphedema, which is the swelling of a body part as a result of fluid retention, is the most frequent cause of angiosarcoma. Carcinogens like vinyl chloride, arsenic, and thorium dioxide are linked to angiosarcoma, which can also be brought on by radiation exposure or treatment.

Angiosarcoma (Epidemiology)

Angiosarcoma is a rare tumor, and even though less than 0.1% of head and neck malignancies occur in the head and neck, angiosarcomas develop there in about 50% of cases. Angiosarcomas make up about 2% of soft tissue tumors overall and 54% of cutaneous soft tissue tumors. The incidence of soft tissue tumors was 5.9 per 100,000 people from 1973 to 2006. Global infection rates are also low; for instance, the National Cancer Intelligence Network (NCIN) reports that angiosarcomas account for 3.3 % of all soft tissue tumors in the United Kingdom with an incidence of 1.5. Demographic differences include cutaneous angiosarcoma is uncommon among African Americans in the United States, cutaneous angiosarcoma is more common in men than women, with a 2:1 male-to-female ratio, and soft tissue are the most common types. Most frequently affecting adults (ages 2-7), angiosarcomas of the head and neck typically affect older people.

Angiosarcoma -Current Market Size & Forecast Trends

The angiosarcoma treatment market is currently valued at approximately USD 275.14 million in 2023 and is projected to grow significantly, reaching around USD 1.8 billion by 2035, with a compound annual growth rate (CAGR) of 6% during the forecast period. Key trends influencing this market include increasing awareness and early detection of angiosarcoma, advancements in targeted therapies and immunotherapy, and rising research funding dedicated to rare cancers. North America is expected to maintain a dominant market share due to its advanced healthcare infrastructure and ongoing investment in cancer research, while the Asia-Pacific region is anticipated to experience the fastest growth, driven by a growing elderly population and improved access to healthcare services. The focus on personalized medicine and innovative treatment options is likely to further enhance market dynamics as more effective therapies are developed to address this aggressive form of cancer.

The highly malignant ependymoma angiosarcoma has a high rate of both local and distant recurrence. Histological examination is the only reliable technique for making an accurate diagnosis of angiosarcoma due to its pathological diversity. The cause of the majority of newly developing angiosarcomas is unknown. Angiosarcoma treatments available today have drawbacks. However, the mainstay of treatment for patients with localized angiosarcoma continues to be surgical resection with adjuvant radiotherapy. It is challenging to stop metastases from returning after treatment. Although it is limited by the toxicity of frequently prescribed drugs for treatment, chemotherapy is still the primary treatment option for metastatic hemangiomas. Biotherapy is the field most likely to find the best treatment options for this rare disease as our understanding of disease biology continues to advance. Targeted medications promise increased survival, progression-free OS, and even total angiosarcoma remission. In order to improve prevention, early diagnosis, and efficient treatment, more prospective studies are generally required. Osteosarcoma is typically treated with up to 3 months of preoperative chemotherapy (adjuvant or induction chemotherapy), then a necessary recovery period after surgery. If there are no additional complications or additional procedures needed, this process can typically take up to a year. Surgery to remove soft tissue sarcomas is typically followed by radiation therapy (usually lasting around 5 weeks), either with or without chemotherapy. Although the decision to administer radiation therapy before, after, and after surgery is somewhat debatable (or may vary from case to case), it is unquestionably a crucial component of the treatment strategy for these tumors. By extension, the patient becomes more challenging and needs daily care for about five weeks.

Report Highlights

Angiosarcoma - Current Market Trends

Angiosarcoma - Current & Forecasted Cases across the G8 Countries

Angiosarcoma - Market Opportunities and Sales Potential for Agents

Angiosarcoma - Patient-based Market Forecast to 2035

Angiosarcoma - Untapped Business Opportunities

Angiosarcoma - Product Positioning Vis-a-vis Competitors' Products

Angiosarcoma - KOLs Insight